Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:synthetic_ligand
gptkb:chemical_compound |
| gptkbp:CASNumber |
1225847-05-7
|
| gptkbp:developedBy |
GlaxoSmithKline
|
| gptkbp:effect |
inhibits LXR-mediated gene expression
|
| gptkbp:hasMolecularFormula |
C27H24N4O2
|
| gptkbp:heldBy |
Liver X receptor antagonist
|
| gptkbp:IUPACName |
N-(2,2-diphenylethyl)-3-oxo-1,2,4-oxadiazole-5-carboxamide
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2105727
25185745 |
| gptkbp:target |
gptkb:LXRα
gptkb:LXRβ |
| gptkbp:used_in |
biomedical research
|
| gptkbp:used_in_study_of |
atherosclerosis
lipid metabolism cholesterol metabolism |
| gptkbp:bfsParent |
gptkb:LXRα
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
GSK2033
|